Logo Image
|Videos|November 10, 2017

Are Hospital Mattresses Putting Patients at Increased Risk for C. difficile?

Edmond Hooker, MD, DrPH, discusses multiple factors that put patients at increased risk of getting C. difficile.

Edmond Hooker, MD, DrPH, professor, Health Services Administration at Xavier University, and emergency physician at the University of Cincinnati, discusses multiple factors that put patients at increased risk of getting C. difficile.

Interview Transcript (modified slightly for readability):

"You’re at risk for getting C. difficile infections, if you’re getting antibiotics, if you’re on proton pump inhibitors, if people aren’t washing their hands; those kinds of things have been well recognized. But the big risk to inpatients is the mattress. Patients are exposed to the mattress; they’re lying on it for hours on end, and these mattresses cannot be cleaned and are not being cleaned as we are currently doing it today, and we need to change.”

Related to this article

View more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more
LMN-201 Reduces C difficile Recurrence
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Read more